Epigenic Therapeutics, a Shanghai, China-based biotechnology company dedicated to developing gene modulation therapy to treat prevalent diseases, raised $32M in Series A funding.
The round...
Neurophth Therapeutics, a Wuhan, China-based gene therapy company for ophthalmic diseases, raised nearly USD95M in Series C+ funding.
The round was led by Yangtze River-CMB...
Unisun Energy Group, a Shanghai, China-based provider of industrial and commercial intelligent green power services, raised an undisclosed amount in Series C funding.
The round...
Atantares, a Beijing, China-based developer of develop molecular chips, closed a Pre-A and Pre-A+ financing all around RMB100m.
The Pre-A round was led by Asia...
Panlin Capital, a Shangai, China-based venture capital firm focusing on Chinese technological innovation, closed its 12th RMB-denominated main fund.
Chengdu Panlin Xiangxu Fund is the first...
Detection Technology, an Espoo, Finland-based provider of X-ray detector solutions and services, acquired Haobo Imaging, a Shanghai, China-based company which specializes in static and...
Eccogene, a Shanghai, China-based clinical-stage biotechnology company, raised CNY180M (approx. $25M) in Series B Equity funding.
The round by co-led by New Alliance Capital and...
Lynk Pharmaceuticals, a Hangzhou, China-based clinical stage company, raised 200M RMB in Series C1 funding.
The round saw participation from China Grand Prosperity Investment, Tailong...
LTZ Therapeutics, a Redwood City, CA- and Shenzen, China-based immunotherapy-focused biotech company, raised over $10m in pre-A+ financing.
The round was led by Qiming...
Cloudsky Technologies, a Shenzen, China-based computing infrastructure and services provider, secured a Series C+ round funding of no less than ten million dollars.
Backers included...
AutoCore.ai, a Nanjing, China-based automotive system software provider, completed its A+ round funding.
The round, whose amount was not disclosed, was led by Bosch Ventures...
ChomiX Biotech, a Nanjing, China-based biotechnology company focusing on the preclinical development of innovative small molecule drugs, raised an undisclosed amount in Series Pre-A+...
